Study on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. Severity of symptoms can be a significant predictor of poor treatment outcomes.
TRINTELLIX® is the first antidepressant to include head-to-head data in its labeling that
showed improvement in treatment-emergent sexual dysfunction in patients with MDD who switched from certain SSRI treatments.
4
SUBSCRIPTION RECEIVED
Thank you for subscribing to the Lundbeck Newsroom newsletter! We'll send the latest news and insights directly to your inbox.
Leaving Site
You are about to leave the NewsRoom website and enter a website operated by an independent third party. The links to third-party websites are provided solely for your convenience. Lundbeck does not control the opinions, claims, or comments contained on any third-party website linked to NewsRoom.com, and your activities at those websites will be governed by the policies and practices of those third parties.
Select "OK" to proceed to this third-party website or "Cancel" to stay at NewsRoom.com.